Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design

Chemico-Biological Interactions

Volumn 192, Issue 1-2, 2011, Pages 56-59

  Humphreys, W Griffith ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytochrome P450 (CYP); Drug design; Reactive metabolites

Indexed keywords

GLUTATHIONE; NEW DRUG;

CONFERENCE PAPER; COVALENT BOND; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROCESS DESIGN; PROCESS OPTIMIZATION;

CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; LIMIT OF DETECTION; TANDEM MASS SPECTROMETRY;

EID: 79958072363     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.01.005     Document Type: Conference Paper

References (39)

1. D.E. Amacher Reactive intermediates and the pathogenesis of adverse drug reactions: the toxicology perspective Current Drug Metabolism 7 3 2006 219 229
2. J.L. Walgren, M.D. Mitchell, and D.C. Thompson Role of metabolism in drug-induced idiosyncratic hepatotoxicity Critical Reviews in Toxicology 35 4 2005 325 361 (Pubitemid 40691298)
3. F.P. Guengerich Mechanisms of drug toxicity and relevance to pharmaceutical development Drug Metabolism and Pharmacokinetics 2010 10.2133/dmpk.DMPK-10-RV-062
4. B.K. Park, H. Laverty, A. Srivastava, D.J. Antoine, D. Naisbitt, and D.P. Williams Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity Chemico-Biological Interactions 192 1-2 2010 30 36
5. F.P. Guengerich, and J.S. MacDonald Applying mechanisms of chemical toxicity to predict drug safety Chemical Research in Toxicology 20 3 2007 344 369 (Pubitemid 46548682)
6. J. Uetrecht Screening for the potential of a drug candidate to cause idiosyncratic drug reactions Drug Discovery Today 8 18 2003 832 837 (Pubitemid 37083340)
7. T.A. Baillie Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism Chemical Research in Toxicology 21 1 2008 129 137 (Pubitemid 351219714)
8. A.S. Kalgutkar, and M.T. Didiuk Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chemistry and Biodiversity 6 11 2009 2115 2137
9. G.A Doss, and T.A. Baillie Addressing metabolic activation as an integral component of drug design Drug Metabolism Reviews 38 4 2006 641 649 (Pubitemid 44903260)
10. S. Kumar, K. Mitra, K. Kassahun, and T.A. Baillie Approaches for minimizing metabolic activation of new drug candidates in drug discovery Handbook of Experimental Pharmacology 196 2010 511 544
11. F.P. Guengerich Generation of reactive intermediates Journal of Biochemical and Molecular Toxicology 19 3 2005 173 174 (Pubitemid 40967286)
12. F.P. Guengerich Cytochrome p450 and chemical toxicology Chemical Research in Toxicology 21 1 2008 70 83 (Pubitemid 351219709)
13. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, K.R. Henne, A.E. Mutlib, D.K. Dalvie, J.S. Lee, Y. Nakai, J.P. O'Donnell, J. Boer, and S.P. Harriman A comprehensive listing of bioactivation pathways of organic functional groups Current Drug Metabolism 6 3 2005 161 225 (Pubitemid 40753853)
14. P.J. Shaw, P.E. Ganey, and R.A. Roth Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity Toxicological Sciences 118 1 2010 7 18
15. D.P. Jones, J.J. Lemasters, D. Han, U.A. Boelsterli, and N. Kaplowitz Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria Molecular Interventions 10 2 2010 98 111
16. D.H. Adams, C. Ju, S.K. Ramaiah, J. Uetrecht, and H. Jaeschke Mechanisms of immune-mediated liver injury Toxicological Sciences 115 2 2010 307 321
17. B.K. Gunawan, and N. Kaplowitz Mechanisms of drug-induced liver disease Clinics in Liver Disease 11 3 2007 459 475 (Pubitemid 47302342)
18. A.K. Daly, and C.P. Day Genetic association studies in drug-induced liver injury Seminars in Liver Disease 29 4 2009 400 411
19. A.R. Hughes, C.H. Brothers, M. Mosteller, W.R. Spreen, and D.K. Burns Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example Pharmacogenomics 10 2 2009 225 233
20. A.K. Daly, P.T. Donaldson, P. Bhatnagar, Y. Shen, I. Pe'er, A. Floratos, M.J. Daly, D.B. Goldstein, S. John, M.R. Nelson, J. Graham, B.K. Park, J.F. Dillon, W. Bernal, H.J. Cordell, M. Pirmohamed, G.P. Aithal, and C.P. Day HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nature Genetics 41 7 2009 816 819
21. A. Kindmark, A. Jawaid, C.G. Harbron, B.J. Barratt, O.F. Bengtsson, T.B. Andersson, S. Carlsson, K.E. Cederbrant, N.J. Gibson, M. Armstrong, M.E. Lagerstrom-Fermer, A. Dellsen, E.M. Brown, M. Thornton, C. Dukes, S.C. Jenkins, M.A. Firth, G.O. Harrod, T.H. Pinel, S.M. Billing-Clason, L.R. Cardon, and R.E. March Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis The Pharmacogenomics Journal 8 3 2008 186 195 (Pubitemid 351712643)
22. A.H. Harrill, P.B. Watkins, S. Su, P.K. Ross, D.E. Harbourt, I.M. Stylianou, G.A. Boorman, M.W. Russo, R.S. Sackler, S.C. Harris, P.C. Smith, R. Tennant, M. Bogue, K. Paigen, C. Harris, T. Contractor, T. Wiltshire, I. Rusyn, and D.W. Threadgill Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Genome Research 19 9 2009 1507 1515
23. H. Takakusa, H. Masumoto, H. Yukinaga, C. Makino, S. Nakayama, O. Okazaki, and K. Sudo Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity Drug Metabolism and Disposition 36 9 2008 1770 1779
24. R.S. Obach, A.S. Kalgutkar, J.R. Soglia, and S.X. Zhao Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chemical Research in Toxicology 21 9 2008 1814 1822
25. S. Nakayama, R. Atsumi, H. Takakusa, Y. Kobayashi, A. Kurihara, Y. Nagai, D. Nakai, and O. Okazaki A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metabolism and Disposition 37 9 2009 1970 1977
26. J.N. Bauman, J.M. Kelly, S. Tripathy, S.X. Zhao, W.W. Lam, A.S. Kalgutkar, and R.S. Obach Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction Chemical Research in Toxicology 22 2 2009 332 340
27. T. Usui, M. Mise, T. Hashizume, M. Yabuki, and S. Komuro Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins Drug Metabolism and Disposition 37 12 2009 2383 2392
28. J. Gan, Q. Ruan, B. He, M. Zhu, W.C. Shyu, and W.G. Humphreys In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation Chemical Research in Toxicology 22 4 2009 690 698
29. D.C. Evans, and T.A. Baillie Minimizing the potential for metabolic activation as an integral part of drug design Current Opinion in Drug Discovery and Development 8 1 2005 44 50 (Pubitemid 40116329)
30. S.O. Simmons, C.Y. Fan, and R. Ramabhadran Cellular stress response pathway system as a sentinel ensemble in toxicological screening Toxicological Sciences 111 2 2009 202 225
31. R. Sawamura, N. Okudaira, K. Watanabe, T. Murai, Y. Kobayashi, M. Tachibana, T. Ohnuki, K. Masuda, H. Honma, A. Kurihara, and O. Okazaki Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide Drug Metabolism and Disposition 38 10 2010 1857 1864
32. Y.Z. Shu, B.M. Johnson, and T.J. Yang Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery The AAPS Journal 10 1 2008 178 192
33. C.M. Dieckhaus, C.L. Fernandez-Metzler, R. King, P.H. Krolikowski, and T.A. Baillie Negative ion tandem mass spectrometry for the detection of glutathione conjugates Chemical Research in Toxicology 18 4 2005 630 638 (Pubitemid 40563277)
34. Z. Yan, N. Maher, R. Torres, G.W. Caldwell, and N. Huebert Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry Rapid Communications in Mass Spectrometry 19 22 2005 3322 3330 (Pubitemid 41682061)
35. A. Mutlib, W. Lam, J. Atherton, H. Chen, P. Galatsis, and W. Stolle Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites Rapid Communications in Mass Spectrometry 19 23 2005 3482 3492 (Pubitemid 41691924)
36. J. Gan, T.W. Harper, M.M. Hsueh, Q. Qu, and W.G. Humphreys Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites Chemical Research in Toxicology 18 5 2005 896 903 (Pubitemid 40705457)
37. D. Argoti, L. Liang, A. Conteh, L. Chen, D. Bershas, C.P. Yu, P. Vouros, and E. Yang Cyanide trapping of minimum ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS) Chemical Research in Toxicology 18 10 2005 1537 1544 (Pubitemid 41504473)
38. G. Tuschl, B. Lauer, and S.O. Mueller Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism Expert Opinion on Drug Metabolism and Toxicology 4 7 2008 855 870
39. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chemical Research in Toxicology 17 1 2004 3 16 (Pubitemid 38134055)